Business Description
uniQure NV
ISIN : NL0010696654
Share Class Description:
QURE: Class BTotal Employee Number:
221Description
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.9 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -0.37 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.3 | |||||
Beneish M-Score | -3.03 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -50.3 | |||||
3-Year EBITDA Growth Rate | 4.3 | |||||
3-Year EPS without NRI Growth Rate | -5.9 | |||||
3-Year FCF Growth Rate | 3.8 | |||||
3-Year Book Growth Rate | -32 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.67 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 184.01 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.05 | |||||
9-Day RSI | 56.1 | |||||
14-Day RSI | 58.85 | |||||
3-1 Month Momentum % | 47.53 | |||||
6-1 Month Momentum % | 134.55 | |||||
12-1 Month Momentum % | 125.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.01 | |||||
Quick Ratio | 10.01 | |||||
Cash Ratio | 9.72 | |||||
Days Sales Outstanding | 96.54 | |||||
Days Payable | 1370.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10 | |||||
Shareholder Yield % | -16.53 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.49 | |||||
Operating Margin % | -1017.18 | |||||
Net Margin % | -1350.73 | |||||
EBITDA Margin % | -915.89 | |||||
FCF Margin % | -864.67 | |||||
OCF Margin % | -861.11 | |||||
ROE % | -140.58 | |||||
ROA % | -31.05 | |||||
ROIC % | -90.91 | |||||
3-Year ROIIC % | 37.21 | |||||
ROC (Joel Greenblatt) % | -696.29 | |||||
ROCE % | -24.96 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 162.23 | |||||
PB Ratio | 10.32 | |||||
Price-to-Tangible-Book | 14.09 | |||||
EV-to-EBIT | -13.99 | |||||
EV-to-Forward-EBIT | 58.22 | |||||
EV-to-EBITDA | -15.17 | |||||
EV-to-Forward-EBITDA | -12.16 | |||||
EV-to-Revenue | 138.96 | |||||
EV-to-Forward-Revenue | 115.86 | |||||
EV-to-FCF | -16.07 | |||||
Price-to-GF-Value | 6.11 | |||||
Price-to-Median-PS-Value | 6.46 | |||||
| Price-to-Net-Current-Asset-Value | 19.29 | |||||
| Price-to-Net-Cash | 22.43 | |||||
Earnings Yield (Greenblatt) % | -7.15 | |||||
FCF Yield % | -4.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QURE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
uniQure NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 18.672 | ||
| EPS (TTM) ($) | -4.01 | ||
| Beta | 1.1171 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 2.91 | ||
| Volatility % | 275.92 | ||
| 14-Day RSI | 58.85 | ||
| 14-Day ATR ($) | 2.154511 | ||
| 20-Day SMA ($) | 47.235575 | ||
| 12-1 Month Momentum % | 125.46 | ||
| 52-Week Range ($) | 8.73 - 71.5 | ||
| Shares Outstanding (Mil) | 69.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
uniQure NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
uniQure NV Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-02 08:00 | In 184 days | ||
| Annual report for 2026 | 2027-03-02 | In 183 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-02 | In 183 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-10 08:30 | In 72 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 71 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | 36.66 (-2.42%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 36.66 (-2.42%) | ||
| General meeting for 2026 | 2026-06-10 09:00 | 26.46 (-3.18%) | ||
| Guidance call for 2026 | 2026-05-19 11:30 | 24.93 (-7.60%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 08:30 | 20.68 (+6.60%) |
Show
Entries
uniQure NV Frequently Asked Questions
What is uniQure NV(QURE)'s stock price today?
The current price of QURE is $48.18. The 52 week high of QURE is $71.50 and 52 week low is $8.73.
When is next earnings date of uniQure NV(QURE)?
The next earnings date of uniQure NV(QURE) is 2026-11-10 Est..
Does uniQure NV(QURE) pay dividends? If so, how much?
uniQure NV(QURE) does not pay dividend.
Guru Commentaries on NAS:QURE
Diamond Hill International
Bullish
2025 Q3
What the manager wrote
Dutch-headquartered biotechnology company uniQure was the top contributor in the quarter. Shares rallied after the company announced positive results from its Phase I/II study of high-dose AMT-130 for Huntington’s disease, as results exceeded expectations and spurred optimism that the future value of potential royalty streams far outstripped prior expectations.
Summers Value Fund
Bullish
2025 Q3
What the manager wrote
We initiated a position in uniQure (QURE) following encouraging Phase 3 results for its gene therapy drug in Huntington’s Disease, which showed a 75% reduction in disease progression – a game-changing outcome in a field that has been devoid of clinical progress. Given the early stage of development, we have sized the position appropriately.
Press Release
Articles on uniQure NV
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers